BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. PCG
2. NVDA
3. AVGO
4. ALNY
5. CNS
6. EC
7. APO
8. SRE
9. ATTO
10. BRVE

Go back to BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

January 12, 2026 7:00 AM EST

Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)

ORLADEYO net revenue expected to be between $625 million and $645 million in 2026

BioCryst expects continued non-GAAP profitability in 2026 even after expected close of the proposed acquisition of Astria Therapeutics in Q1 2026

RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) --... More